目的 探討美沙拉嗪與柳氮磺吡啶治療潰瘍性結(jié)腸炎的臨床療效。方法 將82例潰瘍性結(jié)腸炎患者隨機(jī)分為治療組和對照組,治療組42例,對照組40例。治療組給予美沙拉嗪,對照組給予柳氮磺胺吡啶,治療療程均為6個月。比較兩組的療效和不良反應(yīng)發(fā)生情況。結(jié)果 對照組臨床總有效率67.5%,治療組總有效率為83.3%,兩組比較差異顯著(P<0.05)。腹瀉、腹痛、黏液血便,治療組的總有效率分別為85.4%、86.8%和91.7%,對照組分別為78.9%、75.7%、73.5%。與對照組相比,治療組腹瀉、腹痛、黏液血便等療效改善情況明顯較好(P<0.05);與對照組相比,治療組不良反應(yīng)發(fā)生率明顯較低(P<0.05)。結(jié)論 美沙拉嗪治療潰瘍性結(jié)腸炎療效確切,不良反應(yīng)發(fā)生率低,值得臨床推廣。

Objective To compare the clinical curative effect in the treatment of ulcerative colitis in active phase with mesalazine and salazosulfapyridine. Methods Patients (82 cases) with ulcerative colitis were randomly divided into mesalazine group (42 cases) and salazosulfapyridine group, the groups were respectively given the mesalazine and salazosulfapyridine treatment for a course of 6 months. The curative effect and adverse reactions in two groups were observed. Results The total effective rate of control group was 67.5%, the total effective rate of treatment group was 83.3%, and there was significant difference between the two groups (P < 0.05). Total effective rates of treating diarrhea, abdominal pain, and mucous bloody stool in mesalazine group were 85.4%, 86.8%, and 91.7%, respectively and those in salazosulfapyridine group were 78.9%, 75.7%, and 73.5%, respectively. Comparing the two groups there was no significant difference in diarrhea curative effect, but in abdominal pain, mucous bloody stool efficacy improvement the mesalazine was superior to the salazosulfapyridine group (P < 0.05); The incidence of adverse reactions was 14.3% in mesalazine group, which was obviously lower than the incidence of 22.5% in salazosulfapyridine group, the comparison showed significant difference (P < 0.05). Conclusion Mesalazine for the treatment of ulcerative colitis shows a definite curative effect and lower incidence of adverse reactions, so it is worthy of clinical promotion.